Phenhydan

Quick links to important sections

Phenhydan

Method of action: Antiepileptic

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Phenhydan

Quick Facts: Phenhydan

Property Description
Active ingredient Phenytoin (Phenytoin sodium)
Form Oral capsules, tablets, suspension, and sterile liquid (injectable)
Pharmacological class Anticonvulsant, Antiarrhythmic (Class Ib)
General purpose Stabilizing nerve and heart electrical activity
Origin Synthetic, Hydantoin derivative

What is Phenhydan and What Is Its Composition?

Phenhydan is a prescription-only medication marketed as a single-ingredient product, whose active component is Phenytoin, often formulated as Phenytoin sodium. This substance is a synthetic hydantoin derivative, a chemical classification that distinguishes its structure from newer generation antiepileptic drugs. The availability of Phenhydan in chewable tablets is a differentiating factor, offering a specific oral option for patients who may have difficulty swallowing the extended oral capsules or managing the oral suspension.

The active compound, Phenytoin, has the chemical formula C15H12N2O2. Phenytoin is primarily used to control certain types of seizures. This application has been established over several decades, maintaining its standing as a cornerstone treatment in clinical practice.


What Pharmacological Class and Purpose Define Phenytoin?

Phenytoin is uniquely classified as both a first-generation anti-convulsant and a Class Ib antiarrhythmic agent, placing it in two major therapeutic categories. Phenytoin is widely recognized for its demonstrated effectiveness as an anticonvulsant. This recognition underscores its clinical utility and reliability in managing seizure disorders.

The general purpose of Phenytoin is to reduce the intensity and frequency of abnormal electrical discharges in the body. It achieves this fundamental benefit by stabilizing the electrical excitability of nerve cell membranes through its function as a sodium channel blocker. This stabilizing action means the medication serves the general purpose of managing chronic epilepsy and helps to regulate fast or irregular heart rhythms, showcasing its dual therapeutic utility.

Regulatory References

  1. MedlinePlus Drug Information for Phenytoin

What side effects are possible with Phenhydan?

Possible side effects and safety information

The official safety profile for Phenytoin (Phenhydan) describes adverse reactions by frequency and the body system affected, strictly based on regulatory classifications. The profile addresses effects that are common and expected, as well as rare, serious complications.

Frequency-Classified Adverse Reactions

The adverse reactions are categorized based on incidence rates documented in official regulatory documents:

Classification Examples of Reactions
Very Common Gingival hyperplasia, Nystagmus (involuntary eye movement).
Common Ataxia (loss of coordination), slurred speech, dizziness, nausea, vomiting, and certain skin rashes (morbilliform).

These effects often involve the Nervous System and the Gastrointestinal System, according to System-Organ-Class groupings.

Serious Adverse Reactions and Safety Patterns

The regulatory profile highlights rare but clinically significant adverse reactions. These include severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as well as severe complications involving the Blood and Lymphatic System (e.g., Aplastic Anemia) and the Hepato-biliary System (Acute Hepatic Failure).

Safety patterns are documented regarding the duration of exposure. Dose-related Central Nervous System effects like nystagmus and ataxia are often observed more frequently early in treatment or during dose changes. In contrast, reactions such as gingival hyperplasia and decreased bone mineral density are specifically associated with long-term exposure.

Specific safety considerations exist for populations such as older adults who may be at increased risk of toxicity, and for individuals with pre-existing hepatic impairment. The label also notes that abrupt discontinuation in epileptic patients may precipitate Status Epilepticus.

Overdose and Emergency Response

Phenhydan overdose is primarily defined by a progression of dose-dependent neurotoxicity and the risk of acute cardiovascular instability, as documented in regulatory labeling. Officially documented clinical manifestations begin with central nervous system (CNS) effects such as nystagmus (involuntary eye movement), slurred speech, and ataxia (unsteadiness). These symptoms can advance with increased exposure, potentially leading to profound confusion, tremor, and coma. The regulatory documents state that the most severe outcomes involve the cardiovascular system, which may include life-threatening hypotension and serious cardiac arrhythmias, including ventricular fibrillation and cardiac arrest. Death is a documented outcome in cases of severe toxicity.

Immediate medical attention is required upon any suspicion of overdose. Regulatory guidance mandates contacting emergency services (e.g., Poison Control or 911) without delay. This urgent response is necessary because no specific antidote for Phenhydan overdose is known. Management outlined in prescribing information is limited to symptomatic and supportive treatment, including continuous ECG monitoring and observation of vital signs. Critically ill patients and the elderly are officially noted as being at increased risk for severe cardiovascular complications.

Therapeutic Uses of Phenhydan

What Phenhydan Treats: Main Uses and Benefits

Phenhydan (Phenytoin) is commonly used to address symptoms related to systemic imbalance across multiple therapeutic areas. It is utilized for managing generalized tonic-clonic status epilepticus, and for preventing and managing seizures in the context of neurosurgery.

Long-Term Seizure Control

The medication is commonly used for the long-term management of epilepsy, addressing conditions characterized by episodic or fluctuating symptom patterns like generalized tonic-clonic and complex partial seizures. It helps manage symptoms that appear suddenly and can create noticeable interference with daily stability. This use supports the patient by providing support that helps ease the overall symptom burden associated with seizure episodes and assists with maintaining functional stability.

Acute Support and Specialized Relief

Phenhydan is relevant in clinical settings that involve acute or unstable symptom patterns, such as managing symptoms of Status Epilepticus and preventing seizures that may occur during or following neurosurgical procedures. Furthermore, it plays a role in managing specific fast or irregular heart rhythms (ventricular arrhythmias caused by certain toxicity) and Trigeminal Neuralgia. This dual-domain use means: “The medication is applied when conditions produce significant symptomatic burden due to symptoms of increased neurological or muscular activity.”


Quick Fact: Relief for Symptomatic Manifestations
Primary Focus Managing symptoms of increased neurological or muscular activity and symptoms linked to organ-specific functional stress.
Core Benefit Contributes to easing the overall symptom load and supports general well-being during symptomatic periods.
Clinical Context Used across both chronic management (epilepsy) and acute emergency settings (Status Epilepticus).

Regulatory References

  1. NIH DailyMed drug label overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Phenhydan?

The use of Phenhydan, whose active ingredient is phenytoin, is governed by strict population eligibility rules defined in official regulatory documents.

Absolute Contraindications

Use is prohibited in patients with a history of hypersensitivity to phenytoin, other hydantoins, or its components, and in individuals who have experienced prior acute hepatotoxicity linked to the drug. The injectable form is specifically contraindicated in patients with certain cardiac conduction defects, including Adams-Stokes syndrome and second or third-degree A-V block. Coadministration with the drug delavirdine is also contraindicated.

Age and Conditional Eligibility

Phenhydan is approved for use across adults, adolescents, and pediatric patients for labeled seizure indications. Older adults may require dose adjustments due to decreased drug clearance. Patients with hepatic or renal impairment must have their treatment closely monitored, focusing on the unbound phenytoin concentration. Individuals positive for the *HLA-B15:02** allele are advised to consider avoiding phenytoin due to the documented risk of severe skin reactions.

Reproductive Status

Use during pregnancy is subject to regulatory caution due to the risk of congenital malformations and adverse developmental outcomes. Women of childbearing potential are advised to use effective contraception. Phenytoin is secreted into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Phenhydan (Phenytoin) primarily through alterations in drug exposure. Phenytoin is metabolized by the hepatic enzymes CYP2C9 and CYP2C19. Conversely, Phenytoin is classified as a strong inducer of CYP3A4, meaning it can reduce the plasma concentration and effectiveness of co-administered medicines, such as hormonal contraceptives.

Formal Restrictions

Co-administration with the antiviral medicine Delavirdine is formally contraindicated due to the documented risk of losing the therapeutic response to the antiretroviral treatment. Use with the herbal product St. John's wort is also restricted because it may lead to a clinically significant decrease in Phenytoin plasma concentrations.

Substance and Absorption Effects

Interactions with substances include a two-way effect with alcohol: acute intake may increase Phenytoin levels, while chronic use may cause levels to decrease. Additionally, absorption may be affected by co-administered antacids, which can decrease Phenytoin serum levels. Interpretation of total plasma concentrations requires caution in patients with hepatic impairment or hypoalbuminemia due to altered protein binding.

Mechanism of Action

The mechanism of action for Phenytoin (Phenhydan) is centered on modulation of electrical activity, specifically targeting the movement of sodium ions across excitable cell membranes. The action primarily involves two core mechanistic domains.

Modulating Voltage-Gated Sodium Channels

Phenytoin functions as a use-dependent blocker by targeting the alpha-subunits of voltage-gated sodium channels ( Na^+ channels) in both the central nervous system (CNS) and the heart. The drug binds to and stabilizes the channel in its inactivated state. This molecular action restricts the rapid influx of Na^+ ions required for initiating action potentials. The resulting physiological effect is the restriction of rapid, high-frequency electrical propagation across nerve networks and cardiac muscle.

Selective Suppression of High-Frequency Firing

This mechanism exhibits selectivity because the use-dependent binding is dramatically increased when nerve and cardiac cells are firing at high rates. This preferential engagement with high-frequency firing tissues means the effect is attenuated in tissues operating at normal, low resting frequencies. The resulting physiological consequence is the regulation of membrane excitability by raising the threshold required for cells to generate repetitive action potentials, thereby reducing the capacity for high-frequency action potential generation.

Dosage and Administration Information

How to use Phenhydan

The administration of Phenhydan (Phenytoin) is categorized into two primary routes: oral (PO) for chronic, long-term maintenance and intravenous (IV) for acute, time-critical administration. The intramuscular (IM) route is generally not recommended for acute seizure control due to its slow absorption rate.


Standard Dosing and Frequency

The standard adult maintenance dosage is typically 300 mg to 400 mg per day, which may be taken once daily using the extended-release formulation or divided into multiple doses throughout the day. For acute administration, the initial IV loading dose ranges from 10 mg/kg to 15 mg/kg in adults. Due to the time required to establish a stable concentration of the medicine in the body, dose adjustments generally occur at intervals of 7 to 10 days.


Administration Requirements

Intravenous administration is governed by specific procedural controls. The infusion rate for adults must not exceed 50 mg per minute to ensure controlled delivery. The IV preparation is diluted only with 0.9% Sodium Chloride (Normal Saline); dextrose solutions are not used for dilution due to the risk of precipitation. Furthermore, special consideration for dosing is noted for older adults, who may require lower or less frequent dosing due to decreased metabolic clearance.

Recent Clinical Evidence

Research evidence / Overview of studies for Phenhydan

Phenhydan (Phenytoin) was studied for managing conditions characterized by functional limitations, particularly those involving episodic or acute changes in neurological activity. The research base includes a combination of older and modern Randomized Controlled Trials (RCTs) and comprehensive systematic reviews that contribute to the broader evidence landscape relied upon by regulatory bodies.


Evidence for Long-Term Seizure Management

Research exploring the long-term management of epilepsy often used RCTs where Phenhydan was evaluated alongside other established anti-seizure medications. These studies typically enrolled adults and children who were newly diagnosed with either focal onset or generalized tonic-clonic seizures. The main outcomes research examined included treatment retention and the time until the first recurrence of a seizure. Studies also monitored how symptoms evolved in the observed populations by measuring whether patients reached specific seizure-free remission periods, usually lasting six or twelve months.

However, the evidence quality varies across studies. Because many of the key trials are older, there are methodological concerns, including an elevated risk of bias and heterogeneity (differences) across the study designs used when data are pooled for analysis. There is limited information for long-term outcomes beyond the trial duration, meaning the durability of response over many years is not fully established by high-certainty research.


Evidence for Acute Seizure Control in Emergency Settings

Phenhydan was evaluated in research settings exploring conditions associated with acute or disruptive episodes, specifically convulsive status epilepticus. The primary endpoints studies monitored were the time required for the clinical cessation of convulsive activity and the overall rate of successful termination, which are outcomes describing episodic or acute changes. Researchers also explored follow-up outcomes such as all-cause mortality and neurological status upon hospital discharge.

The certainty of evidence for this application remains low to very low. This is largely due to the challenges of conducting controlled trials in emergency environments, which introduce serious risk of bias and imprecision in the reported outcome data. As a result, the evidence is limited and consistently contributes to understanding short-term changes in an acute, unstable scenario.

Key Studies & References

  1. Phenytoin Oral/Injection Product Labeling (DailyMed)
  2. Phenytoin versus carbamazepine monotherapy for epilepsy: an updated Cochrane review
  3. Phenytoin versus placebo or no intervention for preventing seizures after traumatic brain injury

Frequently Asked Questions (FAQ)

Common questions about Phenhydan (FAQ)

Q: How quickly should someone expect Phenhydan to start working for seizures?

A: According to the official product information, it can take approximately 7 to 10 days of regular oral dosing to achieve a stable concentration of the medicine in the body. This steady level is required for the full intended effect. Intravenous administration is generally used in acute situations to establish the medicine's concentration rapidly.


Q: Why are routine blood tests necessary when taking Phenhydan?

A: Regulatory guidance describes routine blood tests as important for two main reasons. Testing helps ensure the concentration of the medicine stays within the established therapeutic range. It also helps monitor for rare but potentially serious adverse reactions that can affect the blood and liver systems, as documented in the safety profile.


Q: What is meant by the 'therapeutic range' for Phenhydan?

A: The therapeutic range refers to a specific blood concentration level where the medicine is most likely to be effective. For this medicine, that range is commonly cited as 10 to 20 mcg/mL. Maintaining the concentration within this range is generally recognized as a method to achieve therapeutic effect while managing the risk of toxicity, according to official information.


Q: Why does Phenhydan sometimes interact with so many other medications?

A: Regulatory information indicates that Phenhydan is metabolized by specific liver enzymes, known collectively as the CYP450 system. Because this medicine can speed up or slow down these enzyme actions, it can change the concentration of other co-administered medicines, leading to its complex interaction profile.


Q: Does Phenhydan have a narrow therapeutic window?

A: Yes, official drug information resources describe this medicine as having a narrow therapeutic index. This means there is a small margin between the amount needed to be effective and the amount that may cause toxic or adverse effects. This is a key reason why monitoring the blood concentration is important.


Q: What does it mean that Phenhydan is metabolized by the liver’s CYP450 system?

A: Metabolism describes the process where the liver processes and breaks down the medicine so the body can eliminate it. Regulatory documents state that Phenhydan relies on the CYP450 enzyme system for this process. This function is important because other medicines can affect the speed of this system, which in turn causes drug interactions.


Q: Is Phenhydan used for treating conditions other than seizures?

A: Yes, Phenhydan has a dual classification. In addition to being an anti-convulsant for seizures, the medicine is also classified as a Class Ib antiarrhythmic agent. It is officially indicated for the treatment or prevention of certain types of heart rhythm disorders (arrhythmias).


Q: Is Phenhydan a type of narcotic or controlled substance?

A: No, this medicine is a prescription-only drug but is not classified as a controlled substance or narcotic. This factual designation is based on official government listings, such as those maintained by the U.S. Drug Enforcement Administration.


Q: What happens if I miss taking a dose of Phenhydan?

A: Official patient information advises that if you miss a dose, you should take it as soon as possible, unless it is nearly time for the next scheduled dose. If so, you skip the missed dose and resume your normal schedule. Official guidance states that doses should not be doubled to compensate for a missed dose.


Q: Are there different forms of Phenhydan, like liquid or chewable tablets?

A: Yes, the medicine is available in several formulations for different needs. These forms include various oral capsules, tablets (such as chewable options), an oral suspension (liquid), and a sterile solution for injection, as listed in the official product information.


Q: Is it common for Phenhydan to make a person feel tired or sleepy?

A: Yes, common central nervous system adverse reactions are documented in the official safety profile. These include dose-related effects such as somnolence (sleepiness), dizziness, and ataxia, which is a term for loss of coordination.


Q: Can Phenhydan cause changes in mood or behavior?

A: Official safety documentation for this and other antiepileptic agents notes that they may cause or worsen psychiatric symptoms. These can include mood changes, depression, and in rare instances, suicidal ideation and behavior.


Q: Can I switch between generic phenytoin and brand-name Phenhydan?

A: Regulatory documentation notes that minor differences in the amount of medicine absorbed, known as bioavailability, may exist when switching between generic and brand-name formulations. Official information indicates that frequent monitoring of blood levels is often required during any change in formulation.


Q: Does Phenhydan interact with supplements like vitamins or herbal remedies?

A: Yes, regulatory documents note that Phenhydan can interact with certain substances found in supplements. For example, the herbal product St. John's wort is known to decrease levels of the medicine. It can also affect the body’s metabolism of essential supplements, such as Vitamin D, Folate, and Calcium.


Q: Is it possible to develop a rash or allergic reaction from Phenhydan?

A: Yes, skin reactions are a known possibility, as documented in the official safety profile. These can range from common, non-serious rashes like the morbilliform rash, to rare but serious hypersensitivity reactions, including Stevens-Johnson Syndrome (SJS).


Q: Can children take Phenhydan, and is the dosage different?

A: Yes, official regulatory dosing information includes specific guidelines for use in pediatric populations, spanning neonates, infants, and children. For these groups, initial and maintenance dosing is typically calculated based on body weight.


Q: Is it true that Phenhydan can be used for certain heart problems (arrhythmias)?

A: Yes, in addition to being an anti-convulsant, this medicine is officially classified as a Class Ib antiarrhythmic agent. This means it is indicated for the treatment of certain heart rhythm disorders or arrhythmias, according to official labeling.


Q: If I have liver problems, does that change how Phenhydan works?

A: Yes, regulatory documents indicate that the liver is the primary organ responsible for processing this medicine. For individuals with impaired liver function, the rate at which the body clears the medicine may decrease, potentially leading to higher concentrations in the blood and an increased risk of toxicity.


Q: Is it okay to take antacids close to the time I take Phenhydan?

A: Official drug interaction information indicates that certain antacids may decrease the absorption of Phenhydan, potentially leading to lower blood levels. For this reason, the administration of the two medications is typically separated in time to minimize interaction.


Q: Do other medical conditions, like diabetes, affect Phenhydan use?

A: Yes, safety information notes that caution is advised when this medicine is used in patients with diabetes. It may interfere with normal blood sugar regulation and has the potential to potentiate hyperglycemia, which is the term for high blood sugar.


Q: Why is Phenhydan sometimes used after brain surgery?

A: The official indications state that the medicine is used for the prevention and treatment of seizures. This includes those seizures that may occur during or following neurosurgery.


Q: What is the risk of overdose with Phenhydan?

A: Official regulatory information indicates that an overdose may be serious and can involve life-threatening consequences. Symptoms of toxicity are primarily linked to the central nervous system, and can include slurred speech, loss of coordination, and rapid, involuntary eye movements (nystagmus).


Q: Is it true that Phenhydan levels can be affected by eating or fasting?

A: Yes, official information indicates that the body’s absorption of the medicine can be affected by food and feeding status. For instance, specific instructions are provided to separate the administration of the medicine from tube feeding preparations to ensure proper absorption.


Q: Does Phenhydan make seizures worse in some cases?

A: Official regulatory information notes that this medicine may, in rare cases, have a paradoxical effect and precipitate or aggravate certain types of seizures. This risk is specifically documented for absence seizures and myoclonic seizures.


Q: Why is intramuscular (IM) administration of this drug generally not recommended?

A: The intramuscular (IM) route is generally not recommended because the medicine can crystallize at the injection site, which leads to slow and unreliable absorption. For this reason, official guidelines state that IM administration is ineffective for rapidly achieving therapeutic levels.


Q: If a drug interaction is listed, does that mean I absolutely cannot take both medications?

A: Regulatory documents distinguish between a formal contraindication, which is an absolute restriction, and a simple drug interaction. Most listed interactions mean that monitoring of blood levels, dose adjustments, or separation of administration timing may be required, rather than an absolute prohibition.

How should Phenhydan be stored and disposed of?

How to Store and Dispose of Phenhydan

The storage and disposal of Phenhydan (phenytoin) must follow the specific conditions mandated by regulatory labeling to ensure product integrity and safety.


Labeled Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature between 20^circC and 25^circC (68^circF to 77^circF).
Protection Keep the medicine protected from moisture and ensure the container is kept tightly closed and in its original container.
Safety The product must be kept out of the reach of children.

️ Official Disposal Instructions

Unused or expired Phenhydan should be disposed of via a medicine take-back program. If this option is unavailable, the product should be mixed with an undesirable substance, sealed in a container, and placed in the household trash. The medicine must not be flushed down the toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Phenhydan found in:

A-Z Index: